Business Wire

REPLY

23.3.2023 09:01:30 CET | Business Wire | Press release

Share
REPLY: "Everything can become a digital asset" Is the Paradigm Resulting From Reply's ‘Digital Assets Trends’ Research

The digital asset market is growing exponentially. Thanks to blockchain technology and the new generation of operators using tokenization platforms, it is possible to turn everything that can be digitally archived into a digital asset, with recognised value and established ownership. This is what emerges from Reply's new Digital Assets Trends’ research, based on the Reply SONAR platform. By analysing industry studies, scientific articles, patents, documents, and B2B content published in the last year, and integrating concrete experiences from Reply's clients, the study examines the main trends related to digital assets.

Tokenization is the first step to bringing real-world assets and financial instruments onto the blockchain, representing an opportunity especially for those of an illiquid nature (e.g., high-value art, public infrastructure, private equity). The main advantages of tokens include the construction of a peer-to-peer network without intermediaries that also serves as a decentralised network, end-to-end traceability with the possibility of proving ownership at any time, and automated record-keeping that simplifies every aspect of compliance.

"Digital assets still constitute less than 1% of the global financial system, but they have already grown exponentially and will continue this trend in the years to come," commented Filippo Rizzante, CTO of Reply. "Today, Reply is already supporting the demands of various financial institutions, as well as some major players in healthcare, energy, fashion, and public administration, in the adoption of digital assets enabled by a growing maturity of the regulatory framework and the intense work of central banks on their digital currencies."

The study essentially identifies 4 macro-categories of emerging digital assets, these are: payment tokens, non-fungible tokens (NFTs), utility tokens, and security tokens.

Payment tokens include cryptocurrencies and stablecoins. These currencies have not yet been issued by governments or other financial institutions, but are monitored and organised on a decentralised network. This network also serves as a secure ledger for each transaction, pending the first regulations that will come into force in 2024. The rapid and increased circulation of this type of asset has pushed central banks to explore their digital currencies, namely the Central Bank Digital Currencies, and the ECB has also started developing pilot projects for a digital Euro.

Non-fungible tokens are a digital representation of real assets or natively digital assets to be collected or used in virtual worlds. NFTs find application in various sectors, including asset management and the art market. Currently, they are not subject to any regulation and find the greatest potential within the metaverse.

Utility tokens allow the user to perform an action on a specific blockchain or decentralised application. They have been particularly popular for so-called initial coin offerings (ICOs), but today they are mainly used to redeem services and digital products in predefined ecosystems, such as those of cloud or online gaming.

Security tokens are a digital representation of a traditional financial instrument (stocks, bonds and derivatives). As digital assets, they offer additional benefits, including greater flexibility in the creation and distribution process for SMEs and startups. In addition to the existing security tokens that the European Investment Bank launched, the Reply SONAR platform has identified a growing interest in the tokenization of carbon credits, which concern a typically opaque and inefficient market like blockchain technology. This could revolutionise the monetary side of the life cycle of a tokenized carbon offset by tokenizing the credits.

The ‘Digital Assets Trends’ research can be downloaded here.

This study is part of the ‘Reply Trend SONAR’ series, which includes ‘Digital Experience Trends 2023’, ‘Metaverse: the potential beyond the hype’, and ‘Sustainability Trends’.

Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230323005053/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye